Hepion Pharmaceuticals (NASDAQ: HPPI) Advances Liver Cancer Diagnostics with New Biomarker Assay
Market Overview Hepion Pharmaceuticals (NASDAQ: HPPI) continues to garner attention in the biotechnology sector following its recent strategic move to license a cutting-edge ctRNA biomarker assay. This development arrives amid rising investor interest in innovative diagnostic tools targeting early cancer detection, a sector witnessing heightened market activity. The introduction of this next-generation, non-invasive diagnostic platform is expected to bolster Hepion Pharmaceuticals’ standing, potentially influencing HPPI stock positively as the market…
